Advances in G Protein-Coupled Receptor Allostery: From Function to Structure

It is now widely accepted that G protein-coupled receptors (GPCRs) are highly dynamic proteins that adopt multiple active states linked to distinct functional outcomes. Furthermore, these states can be differentially stabilized not only by orthosteric ligands but also by allosteric ligands acting at spatially distinct binding sites. The key pharmacologic characteristics of GPCR allostery include improved selectivity due to either greater sequence divergence between receptor subtypes and/or subtype-selective cooperativity, a ceiling level to the effect, probe dependence (whereby the magnitude and direction of the allosteric effect change with the nature of the interacting ligands), and the potential for biased signaling. Recent chemical biology developments are beginning to demonstrate how the incorporation of analytical pharmacology and operational modeling into the experimental workflow can enrich structure-activity studies of allostery and bias, and have also led to the discovery of a new class of hybrid orthosteric/allosteric (bitopic) molecules. The potential for endogenous allosteric modulators to play a role in physiology and disease remains to be fully appreciated but will likely represent an important area for future studies. Finally, breakthroughs in structural and computational biology are beginning to unravel the mechanistic basis of GPCR allosteric modulation at the molecular level.

[1]  Arthur Christopoulos,et al.  Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.

[2]  Arthur Christopoulos,et al.  Allosteric targeting of receptor tyrosine kinases , 2014, Nature Biotechnology.

[3]  J. Changeux,et al.  International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.

[4]  Lynn R. Webster,et al.  Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers , 2014, PAIN®.

[5]  Vadim Cherezov,et al.  Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs , 2014, Nature Communications.

[6]  P. Sexton,et al.  A new mechanism of allostery in a G protein-coupled receptor dimer , 2014, Nature chemical biology.

[7]  Arthur Christopoulos,et al.  Muscarinic acetylcholine receptors: novel opportunities for drug development , 2014, Nature Reviews Drug Discovery.

[8]  J. Violin,et al.  Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.

[9]  Sarah L. Huszar,et al.  Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target , 2014, Neuropharmacology.

[10]  A. Christopoulos,et al.  Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.

[11]  Vadim Cherezov,et al.  Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.

[12]  Travis S. Hughes,et al.  An alternate binding site for PPARγ ligands , 2014, Nature Communications.

[13]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[14]  Arthur Christopoulos,et al.  Functional and structural perspectives on allosteric modulation of GPCRs. , 2014, Current opinion in cell biology.

[15]  Martin J. Lohse,et al.  G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives , 2014, Pharmacological Reviews.

[16]  Joanne Baltos,et al.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.

[17]  Arthur Christopoulos,et al.  Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.

[18]  Bryan L. Roth,et al.  Molecular control of δ-opioid receptor signalling , 2014, Nature.

[19]  Arthur Christopoulos,et al.  Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor* , 2014, The Journal of Biological Chemistry.

[20]  Cody J. Wenthur,et al.  Drugs for allosteric sites on receptors. , 2014, Annual review of pharmacology and toxicology.

[21]  P. Piazza,et al.  Pregnenolone Can Protect the Brain from Cannabis Intoxication , 2014, Science.

[22]  J. Changeux 50 years of allosteric interactions: the twists and turns of the models , 2013, Nature Reviews Molecular Cell Biology.

[23]  J. Wess,et al.  Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.

[24]  Albert C. Pan,et al.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.

[25]  A. Christopoulos,et al.  A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.

[26]  P. Sexton,et al.  Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. , 2013, Journal of medicinal chemistry.

[27]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[28]  Shane M. Devine,et al.  Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor , 2013, Molecular Pharmacology.

[29]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[30]  Ali Jazayeri,et al.  Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.

[31]  Shailesh N Mistry,et al.  Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. , 2013, Journal of medicinal chemistry.

[32]  D. Riccardi,et al.  The extracellular calcium-sensing receptor, CaSR, in fetal development. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[33]  Jie Zhang,et al.  Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. , 2013, Cancer cell.

[34]  R. Nussinov,et al.  Allostery in Disease and in Drug Discovery , 2013, Cell.

[35]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[36]  P. Sexton,et al.  Allosteric Modulation of a Chemogenetically Modified G Protein-Coupled Receptor , 2013, Molecular Pharmacology.

[37]  P. Sexton,et al.  Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. , 2013, Endocrinology.

[38]  Ulrike Holzgrabe,et al.  Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. , 2013, Angewandte Chemie.

[39]  Arthur Christopoulos,et al.  Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.

[40]  R. N. Takahashi,et al.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor , 2012, Proceedings of the National Academy of Sciences.

[41]  Andrew S. Felts,et al.  Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships , 2012, Molecular Pharmacology.

[42]  B. Lutz,et al.  Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors* , 2012, The Journal of Biological Chemistry.

[43]  U. Holzgrabe,et al.  The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling , 2012, Nature Communications.

[44]  P. Sexton,et al.  Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery , 2012, Molecular Pharmacology.

[45]  Where have all the active receptor states gone? , 2012, Nature chemical biology.

[46]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[47]  Jean Martinez,et al.  Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor , 2012, Proceedings of the National Academy of Sciences.

[48]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[49]  P. Sexton,et al.  Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.

[50]  Bruce J. Melancon,et al.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. , 2012, Journal of medicinal chemistry.

[51]  Shane M. Devine,et al.  Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. , 2012, Journal of medicinal chemistry.

[52]  K. Ahn,et al.  Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation* , 2012, The Journal of Biological Chemistry.

[53]  P. Sexton,et al.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.

[54]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[55]  Malorye Allison,et al.  Reinventing clinical trials , 2012, Nature Biotechnology.

[56]  L. Miller,et al.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol , 2012, Journal of Lipid Research.

[57]  P. Sexton,et al.  Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects , 2012, Molecular Pharmacology.

[58]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[59]  Arthur Christopoulos,et al.  Structure-function studies of muscarinic acetylcholine receptors. , 2012, Handbook of experimental pharmacology.

[60]  P. Sexton,et al.  Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Differentially Regulates Orthosteric but Not Allosteric Agonist Binding and Function* , 2011, The Journal of Biological Chemistry.

[61]  P. Sexton,et al.  Allostery in GPCRs: 'MWC' revisited. , 2011, Trends in biochemical sciences.

[62]  P. Sexton,et al.  A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation* , 2011, The Journal of Biological Chemistry.

[63]  Sudarshan Rajagopal,et al.  Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.

[64]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[65]  A. Christopoulos,et al.  Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors , 2011, Expert opinion on drug discovery.

[66]  C. Langmead,et al.  Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.

[67]  P. Sexton,et al.  Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.

[68]  Elodie Marcon,et al.  Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor. , 2011, European journal of pharmacology.

[69]  A. Christopoulos,et al.  Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. , 2011, The Journal of biological chemistry.

[70]  P. Gmeiner,et al.  Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. , 2011, Journal of medicinal chemistry.

[71]  P. Gmeiner,et al.  Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.

[72]  A. Christopoulos,et al.  Quantification of Functional Selectivity at the Human α1A-Adrenoceptor , 2011, Molecular Pharmacology.

[73]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.

[74]  S. Pechhold,et al.  The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[75]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[76]  C. Boularan,et al.  Meningococcus Hijacks a β2-Adrenoceptor/β-Arrestin Pathway to Cross Brain Microvasculature Endothelium , 2010, Cell.

[77]  Graeme Milligan,et al.  Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes , 2010, Pharmacological Reviews.

[78]  Francesca Zazzeroni,et al.  The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors , 2010, Molecular Pharmacology.

[79]  M. Jacobson,et al.  The M1 Muscarinic Receptor Allosteric Agonists AC-42 and 1-[1′-(2-Methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Bind to a Unique Site Distinct from the Acetylcholine Orthosteric Site , 2010, Molecular Pharmacology.

[80]  A. Conigrave,et al.  Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. , 2010, Pharmacology & therapeutics.

[81]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[82]  P. White,et al.  Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators , 2010, Molecular Pharmacology.

[83]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[84]  P. Sexton,et al.  Prediction of Functionally Selective Allosteric Interactions at an M3 Muscarinic Acetylcholine Receptor Mutant Using Saccharomyces cerevisiae , 2010, Molecular Pharmacology.

[85]  Arthur Christopoulos,et al.  Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor , 2010, Molecular Pharmacology.

[86]  D. Devost,et al.  A Novel Biased Allosteric Compound Inhibitor of Parturition Selectively Impedes the Prostaglandin F2α-mediated Rho/ROCK Signaling Pathway* , 2010, The Journal of Biological Chemistry.

[87]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[88]  P. Sexton,et al.  Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor , 2010, The Journal of Biological Chemistry.

[89]  Judy Lin,et al.  Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.

[90]  U. Holzgrabe,et al.  Rational design of dualsteric GPCR ligands: quests and promise , 2010, British journal of pharmacology.

[91]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[92]  Arthur Christopoulos,et al.  Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias* , 2010, The Journal of Biological Chemistry.

[93]  K. Gregory,et al.  Overview of receptor allosterism. , 2000, Current protocols in pharmacology.

[94]  M. Millan,et al.  The Tetrahydroisoquinoline Derivative SB 269 , 652 Is an Allosteric Antagonist at Dopamine D 3 and D 2 Receptors , 2010 .

[95]  A. Chattopadhyay,et al.  Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells. , 2009, Biochemical and biophysical research communications.

[96]  M. Quirk,et al.  A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.

[97]  Craig W. Lindsley,et al.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.

[98]  Antoine Taly,et al.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.

[99]  Evi Kostenis,et al.  An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators , 2009, Journal of receptor and signal transduction research.

[100]  Arthur Christopoulos,et al.  Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.

[101]  Arthur Christopoulos,et al.  Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.

[102]  W. Zuercher,et al.  Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.

[103]  C. Lindsley,et al.  Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity , 2009, Molecular Pharmacology.

[104]  U. Holzgrabe,et al.  Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  F. Ehlert,et al.  Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes , 2009, Journal of Pharmacology and Experimental Therapeutics.

[106]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[107]  Arthur Christopoulos,et al.  A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.

[108]  Aron W Fenton,et al.  Allostery: an illustrated definition for the 'second secret of life'. , 2008, Trends in biochemical sciences.

[109]  A. Christopoulos,et al.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.

[110]  M. Whittington,et al.  Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1 , 2008, British journal of pharmacology.

[111]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[112]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[113]  M. Thompson,et al.  G protein-coupled receptors disrupted in human genetic disease. , 2008, Methods in molecular biology.

[114]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[115]  Brian K. Kobilka,et al.  High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. , 2007 .

[116]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[117]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[118]  M. Mammen,et al.  A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor , 2007, Molecular Pharmacology.

[119]  J. Galzi,et al.  A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[120]  A. Fryer,et al.  Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[121]  T. Fujita,et al.  An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations , 2007, Proceedings of the National Academy of Sciences.

[122]  W. Catterall,et al.  Voltage-gated ion channels and gating modifier toxins. , 2007, Toxicon : official journal of the International Society on Toxinology.

[123]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[124]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[125]  C. Langmead,et al.  Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. , 2006, Trends in pharmacological sciences.

[126]  U. Holzgrabe,et al.  Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. , 2006, Journal of medicinal chemistry.

[127]  P. Sexton,et al.  GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.

[128]  P. Conn,et al.  A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[129]  P. Conn,et al.  Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[130]  T. Kenakin New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[131]  F. Ehlert Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[132]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[133]  J. Geibel,et al.  L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[134]  J. M. Mathiesen,et al.  Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.

[135]  R. Olsen,et al.  Fishing for allosteric sites on GABA(A) receptors. , 2004, Biochemical pharmacology.

[136]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[137]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[138]  D. Kendall,et al.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors , 2004, British journal of pharmacology.

[139]  E. Borda,et al.  Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome , 1996, Molecular and Cellular Biochemistry.

[140]  S. Lazareno,et al.  Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. , 2004, Molecular pharmacology.

[141]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[142]  F. Wieland,et al.  Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[143]  D. Kerr,et al.  Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex. , 2003, European journal of pharmacology.

[144]  P. Sexton,et al.  Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.

[145]  B. Kobilka,et al.  Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor* , 2003, The Journal of Biological Chemistry.

[146]  A. C. C. Carvalho,et al.  H uman chagasic IgGs bind to cardiac muscarinic receptors and impair 2 1 L-type Ca currents , 2003 .

[147]  T. Schwartz,et al.  Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.

[148]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[149]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[150]  A. Christopoulos Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[151]  B. Kobilka,et al.  Allosteric Modulation of β2-Adrenergic Receptor by Zn2+ , 2002 .

[152]  Willem Soudijn,et al.  Allosteric modulation of G-protein-coupled receptors , 2001 .

[153]  D. Sibley,et al.  The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.

[154]  A. Christopoulos Overview of Receptor Allosterism , 2000 .

[155]  E. Brown,et al.  L-amino acid sensing by the extracellular Ca2+-sensing receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[156]  L. Prézeau,et al.  Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. , 2000, Molecular pharmacology.

[157]  P B Hedlund,et al.  Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.

[158]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[159]  M Morfis,et al.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.

[160]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[161]  E. Borda,et al.  Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies. , 1999, Cardiovascular research.

[162]  J. Sutcliffe,et al.  Oleamide‐induced Modulation of 5‐Hydroxytryptamine Receptor‐mediated Signaling a , 1998, Annals of the New York Academy of Sciences.

[163]  D. Colquhoun,et al.  Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.

[164]  U. Holzgrabe,et al.  Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors. , 1998, Molecular pharmacology.

[165]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[166]  Hans H. Zingg,et al.  Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.

[167]  M. Neal,et al.  Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[168]  J L Benovic,et al.  Agonist-Receptor-Arrestin, an Alternative Ternary Complex with High Agonist Affinity* , 1997, The Journal of Biological Chemistry.

[169]  G. Gimpl,et al.  Cholesterol as modulator of receptor function. , 1997, Biochemistry.

[170]  E. Borda,et al.  Desensitization and Sequestration of Human m2 Muscarinic Acetylcholine Receptors by Autoantibodies from Patients with Chagas’ Disease* , 1997, The Journal of Biological Chemistry.

[171]  D. Sibley,et al.  Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors , 1997, Journal of neurochemistry.

[172]  P. Hedera,et al.  Delirium in Alzheimer Disease , 1997, Alzheimer disease and associated disorders.

[173]  W W Offen,et al.  The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. , 1997, Alzheimer disease and associated disorders.

[174]  R. Hen,et al.  5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.

[175]  M. Delepierre,et al.  Isolation and Characterization of an Endogenous Peptide from Rat Brain Interacting Specifically with the Serotonergic 1B Receptor Subtypes (*) , 1996, The Journal of Biological Chemistry.

[176]  E. Zifa,et al.  A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT 1B 1D receptors , 1995, Behavioural Brain Research.

[177]  M. Spedding,et al.  New drug binding sites in Ca2+ channels. , 1995, Trends in pharmacological sciences.

[178]  P P Humphrey,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.

[179]  G. Gleich,et al.  Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. , 1993, The Journal of clinical investigation.

[180]  J. Ellis,et al.  Two allosteric modulators interact at a common site on cardiac muscarinic receptors. , 1992, Molecular pharmacology.

[181]  J. Traynor,et al.  Differential Effects of Mg2+ and Other Divalent Cations on the Binding of Tritiated Opioid Ligands , 1992, Journal of neurochemistry.

[182]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[183]  M. Spedding,et al.  Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand , 1987, British journal of pharmacology.

[184]  F. Ehlert The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.

[185]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[186]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[187]  H. Yamamura,et al.  Modulation of benzodiazepine receptor binding: insight into pharmacological efficacy. , 1982, European journal of pharmacology.

[188]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[189]  P. Krogsgaard‐Larsen,et al.  Partial agonists for brain GABA/benzodiazepine receptor complex , 1979, Nature.

[190]  R. Lefkowitz,et al.  Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. , 1978, The Journal of biological chemistry.

[191]  F. Mitchelson,et al.  THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.

[192]  S. Snyder,et al.  Selective enhancement of [3H]opiate agonist binding by divalent cations. , 1975, Molecular pharmacology.

[193]  E. J. Simon,et al.  Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[194]  S. Snyder,et al.  Opiate Agonists and Antagonists Discriminated by Receptor Binding in Brain , 1973, Science.

[195]  W. Wooster,et al.  Crystal structure of , 2005 .

[196]  O. Wassermann,et al.  Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.

[197]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.

[198]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[199]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.

[200]  H. Kowarzyk Structure and Function. , 1910, Nature.